Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women

Osteoporosis International

Volumn 22, Issue 5, 2011, Pages 1459-1468

  Yin, M T ^a   Modarresi, R ^b   Shane, E ^a   Santiago, F ^b   Ferris, D C ^c   McMahon, D J ^a   Zhang, C A ^a   Cremers, S ^a   Laurence, J ^b  

^a NewYork Presbyterian Hospital   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BRONX LEBANON HOSPITAL CENTER   (United States)

Author keywords

Bone; HIV; Osteoclast; Postmenopausal; Protease inhibitor

Indexed keywords

ATAZANAVIR; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; CYTOKINE; ESTRADIOL; ESTRONE; FOLLITROPIN; FOSAMPRENAVIR; LOPINAVIR; OSTEOCLAST DIFFERENTIATION FACTOR; RITONAVIR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY FAT; BONE DENSITY; BONE TURNOVER; CD4 LYMPHOCYTE COUNT; CELL ADHESION; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRONE BLOOD LEVEL; FEMALE; FEMUR NECK; FOLLITROPIN BLOOD LEVEL; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HISPANIC; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MORPHOMETRICS; OSTEOCLAST; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTMENOPAUSE; PRIORITY JOURNAL; THERAPY EFFECT;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; OSTEOCLASTS; PILOT PROJECTS; POSTMENOPAUSE; RITONAVIR;

EID: 79955484368     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1363-6     Document Type: Article

References (42)

1. TT Brown RB Qaqish 2006 Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review AIDS 20 2165 2174 17086056 10.1097/QAD.0b013e32801022eb (Pubitemid 44684707)
2. MJ Bolland AB Grey GD Gamble IR Reid 2007 Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis J Clin Endocrinol Metab 92 4522 4528 17925333 10.1210/jc.2007-1660 1:CAS:528:DC%2BD1cXmslWhtr0%3D (Pubitemid 350223420)
3. S Grinspoon C Corcoran K Miller BM Biller H Askari E Wang J Hubbard EJ Anderson N Basgoz HM Heller A Klibanski 1997 Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting J Clin Endocrinol Metab 82 1332 1337 9141512 10.1210/jc.82.5.1332 1:CAS:528: DyaK2sXjtVGmtLs%3D (Pubitemid 27200397)
4. J Cofrancesco Jr JJ Whalen 3rd AS Dobs 1997 Testosterone replacement treatment options for HIV-infected men J Acquir Immune Defic Syndr Hum Retrovirol 16 254 265 9402072 1:CAS:528:DyaK1cXltFOi
5. EJ Cotter AP Malizia N Chew WG Powderly PP Doran 2007 HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development AIDS Res Hum Retroviruses 23 1521 1530 18160010 10.1089/aid.2007.0112 1:CAS:528:DC%2BD1cXhtVKquw%3D%3D
6. D Gibellini E De Crignis C Ponti L Cimatti M Borderi M Tschon R Giardino MC Re 2008 HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation J Med Virol 80 1507 1514 18649336 10.1002/jmv.21266 1:CAS:528:DC%2BD1cXhtVajtbfK
7. AE Kearns S Khosla PJ Kostenuik 2008 Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr Rev 29 155 192 18057140 10.1210/er.2007-0014 1:CAS:528: DC%2BD1cXltlOhsr0%3D (Pubitemid 351519689)
8. A Carr J Miller JA Eisman DA Cooper 2001 Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy AIDS 15 703 709 11371684 10.1097/00002030-200104130- 00005 1:STN:280:DC%2BD3M3nt1KisQ%3D%3D (Pubitemid 32423217)
9. H Knobel A Guelar G Vallecillo X Nogues A Diez 2001 Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15 807 808 11371701 10.1097/00002030-200104130-00022 1:STN:280:DC%2BD3M3nt1Khtg%3D%3D (Pubitemid 32423234)
10. AL Moore A Vashisht CA Sabin A Mocroft S Madge AN Phillips JW Studd MA Johnson 2001 Reduced bone mineral density in HIV-positive individuals AIDS 15 1731 1733 11546951 10.1097/00002030-200109070-00019 1:STN:280: DC%2BD3Mvpsl2msw%3D%3D (Pubitemid 32918130)
11. P Tebas WG Powderly S Claxton D Marin W Tantisiriwat SL Teitelbaum KE Yarasheski 2000 Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy AIDS (London, England) 14 F63 F67 10.1097/00002030-200003100-00005 1:CAS:528:DC%2BD3cXis1egu7w%3D (Pubitemid 30182458)
12. D Bruera N Luna DO David LM Bergoglio J Zamudio 2003 Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy AIDS 17 1917 1923 12960824 10.1097/00002030-200309050-00010 (Pubitemid 37070277)
13. JE Gallant S Staszewski AL Pozniak E DeJesus JM Suleiman MD Miller DF Coakley B Lu JJ Toole AK Cheng 2004 Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 191 201 15249568 10.1001/jama.292.2.191 1:CAS:528:DC%2BD2cXlvVSnur0%3D (Pubitemid 38917996)
14. JS Huang P Rietschel CM Hadigan DI Rosenthal S Grinspoon 2001 Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy AIDS 15 975 982 11399979 10.1097/00002030-200105250-00005 1:STN:280:DC%2BD3MzjtVylug%3D%3D (Pubitemid 32476664)
15. S Landonio T Quirino P Bonfanti A Gabris L Boccassini C Gulisano L Vulpio E Ricci M Carrabba GM Vigevani 2004 Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART Biomed Pharmacother 58 505 508 15511607 10.1016/S0753-3322(04)00129-5 1:CAS:528:DC%2BD2cXptFOmu7c%3D (Pubitemid 39423598)
16. D Nolan R Upton E McKinnon M John I James B Adler G Roff S Vasikaran S Mallal 2001 Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir AIDS 15 1275 1280 11426072 10.1097/00002030-200107060-00009 1:CAS:528:DC%2BD3MXlsFSgs7o%3D (Pubitemid 32592360)
17. JM Fakruddin J Laurence 2003 HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk J Biol Chem 278 48251 48258 12975380 10.1074/jbc.M304676200 1:CAS:528:DC%2BD3sXpt1Gjtrw%3D (Pubitemid 37523280)
18. RG Jain JM Lenhard 2002 Select HIV protease inhibitors alter bone and fat metabolism ex vivo J Biol Chem 277 19247 19250 11937496 10.1074/jbc.C200069200 1:CAS:528:DC%2BD38XksVWlt7o%3D (Pubitemid 34967427)
19. AP Malizia E Cotter N Chew WG Powderly PP Doran 2007 HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts AIDS Res Hum Retroviruses 23 243 250 17331030 10.1089/aid.2006.0084 1:CAS:528: DC%2BD2sXislCktb4%3D (Pubitemid 46418337)
20. P Rivas M Gorgolas R Garcia-Delgado M Diaz-Curiel A Goyenechea ML Fernandez-Guerrero 2008 Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir HIV Med 9 89 95 18093130 10.1111/j.1468-1293.2007.00525.x 1:CAS:528: DC%2BD1cXjsl2lurw%3D (Pubitemid 351228131)
21. C Duvivier S Kolta L Assoumou J Ghosn S Rozenberg RL Murphy C Katlama D Costagliola 2009 Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients AIDS 27 817 824 10.1097/QAD. 0b013e328328f789
22. SL Teitelbaum 2000 Bone resorption by osteoclasts Science 289 1504 1508 10968780 10.1126/science.289.5484.1504 1:CAS:528:DC%2BD3cXmt1KgsLk%3D
23. SL Teitelbaum 2007 Osteoclasts: what do they do and how do they do it? Am J Pathol 170 427 435 17255310 10.2353/ajpath.2007.060834 1:CAS:528: DC%2BD2sXitlOls74%3D (Pubitemid 47339379)
24. R Modarresi Z Xiang M Yin J Laurence 2009 WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss Am J Pathol 174 123 135 19095956 10.2353/ajpath.2009.080484 1:CAS:528:DC%2BD1MXhslOlu7k%3D
25. M Konishi K Takahashi E Yoshimoto K Uno K Kasahara K Mikasa 2005 Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients AIDS 19 1240 1241 15990584 10.1097/01.aids.0000176231.24652.02 (Pubitemid 41059272)
26. MT Yin DJ McMahon DC Ferris CA Zhang A Shu R Staron I Colon J Laurence JF Dobkin SM Hammer E Shane 2010 Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women J Clin Endocrinol Metab 95 620 629 19965927 10.1210/jc.2009-0708 1:CAS:528:DC%2BC3cXitVaisrc%3D
27. M Husheem JK Nyman J Vaaraniemi HK Vaananen TA Hentunen 2005 Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay Calcif Tissue Int 76 222 230 15692727 10.1007/s00223-004-0123-z 1:CAS:528:DC%2BD2MXjs1Cjs7s%3D (Pubitemid 41557151)
28. K Henriksen LB Tanko P Qvist PD Delmas C Christiansen MA Karsdal 2007 Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases Osteoporos Int 18 681 685 17124552 10.1007/s00198-006-0286-8 1:STN:280:DC%2BD2s7ptFGltQ%3D%3D (Pubitemid 46525540)
29. SD Neale E Schulze R Smith NA Athanasou 2002 The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease QJM 95 233 240 11937650 10.1093/qjmed/95.4.233 1:STN:280:DC%2BD383gsFSntw%3D%3D (Pubitemid 34413730)
30. CT Ritchlin SA Haas-Smith P Li DG Hicks EM Schwarz 2003 Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 111 821 831 12639988 1:CAS:528: DC%2BD3sXitlOjsbc%3D (Pubitemid 37074957)
31. MG Gregoretti L Bergui M Aragno O Cremona PC Marchisio F Caligaris-Cappio 1995 Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma Leukemia 9 1392 1397 7643630 1:STN:280: DyaK2MzntFeksg%3D%3D
32. JM Brenchley DA Price TW Schacker TE Asher G Silvestri S Rao Z Kazzaz E Bornstein O Lambotte D Altmann BR Blazar B Rodriguez L Teixeira-Johnson A Landay JN Martin FM Hecht LJ Picker MM Lederman SG Deeks DC Douek 2006 Microbial translocation is a cause of systemic immune activation in chronic HIV infection Nat Med 12 1365 1371 17115046 10.1038/nm1511 1:CAS:528:DC%2BD28Xht1OntbnK (Pubitemid 44924494)
33. G Poli 2004 T lymphocytes of HIV-positive individuals: preloaded guns in spite of highly active antiretroviral therapy? AIDS 18 327 328 15075553 10.1097/00002030-200401230-00025 1:CAS:528:DC%2BD2cXislarsb4%3D (Pubitemid 38253458)
34. DA Glass 2nd G Karsenty 2006 Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation Ann NY Acad Sci 1068 117 130 16831912 10.1196/annals.1346.015 1:CAS:528:DC%2BD28XntFentLc%3D (Pubitemid 43824143)
35. RG Jain ES Furfine L Pedneault AJ White JM Lenhard 2001 Metabolic complications associated with antiretroviral therapy Antivir Res 51 151 177 11448728 10.1016/S0166-3542(01)00148-6 1:CAS:528:DC%2BD3MXltVehsLY%3D (Pubitemid 32622833)
36. MW Wang S Wei R Faccio S Takeshita P Tebas WG Powderly SL Teitelbaum FP Ross 2004 The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling J Clin Invest 114 206 213 15254587 1:CAS:528:DC%2BD2cXlvFWmsLY%3D (Pubitemid 39071625)
37. AV Neutzsky-Wulff MA Karsdal K Henriksen 2008 Characterization of the bone phenotype in ClC-7-deficient mice Calcif Tissue Int 83 425 437 18958510 10.1007/s00223-008-9185-7 1:CAS:528:DC%2BD1cXhsVCnurnK
38. T Segovia-Silvestre AV Neutzsky-Wulff MG Sorensen C Christiansen J Bollerslev MA Karsdal K Henriksen 2009 Advances in osteoclast biology resulting from the study of osteopetrotic mutations Hum Genet 124 561 577 18987890 10.1007/s00439-008-0583-8 1:STN:280:DC%2BD1M%2FgtlelsA%3D%3D
39. SL Alatalo KK Ivaska SG Waguespack MJ Econs HK Vaananen JM Halleen 2004 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis) Clin Chem 50 883 890 15016726 10.1373/clinchem.2003.029355 1:CAS:528:DC%2BD2cXjvVakt7Y%3D (Pubitemid 38543667)
40. DC Bauer PM Sklarin KL Stone DM Black MC Nevitt KE Ensrud CD Arnaud HK Genant P Garnero PD Delmas H Lawaetz SR Cummings 1999 Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures J Bone Miner Res 14 1404 1410 10457273 10.1359/jbmr.1999.14.8.1404 1:STN:280:DyaK1MzovVahsw%3D%3D (Pubitemid 29368303)
41. A Rogers RA Hannon R Eastell 2000 Biochemical markers as predictors of rates of bone loss after menopause J Bone Miner Res 15 1398 1404 10893690 10.1359/jbmr.2000.15.7.1398 1:CAS:528:DC%2BD3cXltFSiurY%3D (Pubitemid 30413874)
42. Yin MT, McMahon DJ, Ferris DC, Shu A, Zhang CA, Laurence J, Shane E (2009) Bone loss in HIV+ postmenopausal women. In American Society for Bone and Mineral Research 31st Annual Meeting, Denver, 11-15 Sep 2009